Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
about
Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.Prucalopride for constipation.The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations.Inhibition of HERG potassium channels by the antimalarial agent halofantrineRehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1Mechanism and pharmacological rescue of berberine-induced hERG channel deficiencyMechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition.Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.Modification of distinct ion channels differentially modulates Ca2+ dynamics in primary cultured rat ventricular cardiomyocytes.Temperature Effects on Kinetics of KV11.1 Drug Block Have Important Consequences for In Silico Proarrhythmic Risk Prediction.A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.Comparison of the effects of metoclopramide and domperidone on HERG channels.Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner.Functional and pharmacological properties of canine ERG potassium channels.State dependent dissociation of HERG channel inhibitorsCisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.Age-related differences in the direct cardiac effects of cisapride: narrower safety range in the hearts of young rabbits.Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details.Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds.Turbulent electrical activity at sharp-edged inexcitable obstacles in a model for human cardiac tissue.High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.Assessment of temperature-induced hERG channel blockade variation by drugs.Temperature dependence of human ether-a-go-go-related gene K+ currents.Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities
P2860
Q33145803-5BA42536-F031-49B9-8C66-E1E9B8649BD7Q34094831-CF8D8EBE-6227-4F89-B510-C3EE1E8B5D90Q34429636-B8A82DC0-C08F-4365-B109-EF60775E49EAQ35042577-52D14EDB-57F2-464A-A64A-C0E74553E4F0Q35114020-E94C064D-8DE4-4604-A4B9-04FD82A26566Q35794534-8CD85361-5CCA-4731-8EEE-6BC6FFFB62CEQ36212952-47C44D97-8EB3-4C72-B2B8-30B964497716Q36945811-ACF471E0-615D-4D42-981B-1B4C717C6BD1Q37411148-B5BC179D-079F-42B8-994C-5545F6517A1CQ37466831-C3894539-7E16-4EE7-AF56-D5F8E56F1208Q37593391-929CCBD2-F7E2-4471-8EF8-0F965102E995Q39758131-4295AD60-00E3-45F1-837E-77A08AB745C0Q39767396-19EA7BBC-DB7E-4A73-B017-EDA173EDF90FQ40045695-15D4E23B-4F87-4E2A-BBC4-2CBEB76C12E7Q40473349-3AAE2AF4-4757-40FE-8FD5-60DB63F81F25Q40675278-CE32ED5E-66D8-47D3-AC76-FD14DB4514EFQ40696231-5B645260-D43B-4DD7-A68E-1854E08468AEQ42624565-2AB95BEE-11B0-403E-B8F0-0C95D233FBD9Q44148256-C9479BAC-1123-436D-A225-990217EDBC22Q44321540-1978572F-DFFA-40F5-B498-1B20C33DD505Q46701565-819353BE-B9B2-47AB-AFEA-1D821FD20CA3Q47095257-44736199-F877-4DE0-AF2F-E27DE5818EF0Q47753818-F6030823-A8E7-466D-B303-CFE39626BE11Q49053130-71F2DB86-8E36-438E-B85A-ABD6B4192005Q51305938-77ADED0A-F526-4B84-B6EF-58330721529BQ51746208-D75D8A2E-336D-4CC6-9DDE-25D5CC61B3AAQ51810570-B878592B-3CA2-40D1-A915-C56524D73CA0Q58553697-7AB56D53-5F87-4972-8623-750D47194C1B
P2860
Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Inhibition of the human ether- ...... r open and inactivated states.
@ast
Inhibition of the human ether- ...... r open and inactivated states.
@en
type
label
Inhibition of the human ether- ...... r open and inactivated states.
@ast
Inhibition of the human ether- ...... r open and inactivated states.
@en
prefLabel
Inhibition of the human ether- ...... r open and inactivated states.
@ast
Inhibition of the human ether- ...... r open and inactivated states.
@en
P2093
P2860
P356
P1476
Inhibition of the human ether- ...... or open and inactivated states
@en
P2093
B D Walker
C B Singleton
J A Bursill
T J Campbell
P2860
P304
P356
10.1038/SJ.BJP.0702774
P407
P577
1999-09-01T00:00:00Z